Researchers have been unable to determine why some depression patients respond better than others to the class of drugs that includes Prozac, Zoloft and Celexa. Now a team has uncovered a gene that may act as a biomarker for this type of patient, potentially helping to match the drug with the patient.
Scientists believe that for the first time, they have linked the gene CUX1 to the development of one in every 100 tumors in cancer patients.
The number of failures in the Alzheimer's drug research field has been piling up disproportionately compared to successes in recent years, and the New York Academy of Sciences is hoping to change that by proposing a more streamlined, efficient path for Alzheimer's drug development.
Narges Bani Asadi, founder and CEO of Bina Technologies By Narges Bani Asadi One of the elements lacking in the personalized medicine discussion today is the perspective of clinicians and...
Scientists have found a new biomarker that can predict whether BRAF-mutant melanomas respond to drugs targeting BRAF, a discovery that could help better tailor treatment therapies for patients with these cancers.
Quintiles, the world's largest CRO, has launched a study to determine whether preprofiling cancer patients for key biomarkers can ease trial enrollment and speed drug development.
Quintiles has kicked off a study to determine whether early genomic profiling of cancer patients can help inform physician decisions and match the right participant with the right study, a method the CRO said could speed up the development process of personalized drugs.
Now that targeted therapies like Roche's Zelboraf and Bayer's Stivarga have raced through the FDA and into patients' hands, drug developers are relying less and less on old-fashioned randomized controlled trials.
As genetic sequencing technology advances and scientists begin to unravel the underlying genetic factors in various types of cancer, it is now increasingly possible to find out why promising drugs have little or no effect in some patients and identify in which populations they have the most potential.
Diagnostics outfit Foundation Medicine is hopping on the IPO bandwagon. It said it plans to raise $75 million by offering 5 million shares at a price range of $14 to $16.